'Wonder' Drug Might be Ineffective in Alcohol Use Disorders

Meta-analysis is an advanced statistical procedure that enables the analyst to merge the results of all the available research on a specific topic into a measurable quantity that represents the quantum of the overall effect of one variable on another variable (for example anxiety on drinking). Thus, meta-analysis involves collective study and offers more precise and reliable results when compared to the outcome of just a single research or study.

Advertisement

Key findings of the meta-analysis were the following:

• Baclofen resulted in higher abstinent rates compared with placebo; for every 8 persons treated with baclofen, one remained abstinent

However, all other outcomes analyzed did not show any relation to baclofen effect

• Baclofen failed to increase number of abstinent days or reduce number of heavy drinking days during the treatment
• Baclofen did not reduce anxiety, depression or craving for alcohol all of which are risk factors for a heavy drinking outcome

Thus, the meta-analysis failed to find conclusive evidence to support the use of baclofen in treating alcohol abuse disorders.

Dr Rose, said: "Our research highlights several issues with the existing body of trials." Many of the studies only recruited a limited number of patients, so maybe too small to find an effect.

"The existing trials also differ on a number of factors, such as the dose of baclofen given and the length of treatment. Importantly, the pharmacokinetics of baclofen (how it moves in the body) are not well-understood, so there may be individual factors influencing the effectiveness of baclofen that we do not yet understand."

Potential Limitation of Earlier Studies Supporting Use of Baclofen In Alcohol Disorders

Several studies have found baclofen to be highly effective in treating alcohol use disorders; some have claimed it to be 'wonder drug' capable of treating alcoholism. Following numerous successful clinical trials, the use of use of baclofen for this purpose increased several fold and sales of the drug increased in a few countries.

However, in more recent years, there has been an increasing number of studies which directly compared baclofen against placebo on a number of outcome measures. Most of these outcome measures are drink-related, for instance

• Degree of abstinence at the end of the treatment trial
• Number of abstinent or heavy drinking days during the trial

However, there are other risk factors identified with excessive drinking andthe role of baclofen in addressing these risk factors may not have been adequately quantified while recommending the use of baclofen in alcohol abuse disorders.

Certain factors have been identified, namely the following such as whether

• Baclofen could reduce alcohol craving
• Baclofen can decrease negative mood states, such as anxiety and depression, which are well-known risk factors for harmful drinking

The current meta-analysis therefore conducted their study to focus on the effectiveness of baclofen in reducing these risk factors leading to harmful drinking.

It may be apt to conclude with the remarks of Dr Jones, who says, "This new meta-analysis shows that baclofen is no more effective than placebo on a range of key outcome measures, suggesting that the current increasing use of baclofen as a treatment for alcohol use disorders is premature."

References :

1. Baclofen - (https://en.wikipedia.org/wiki/Baclofen)

Source: Medindia